The FDA -Agency of the Medicine of the United States-, has just given its approval so that it can be marketed the first medical device, which is based on brain function to assess attention deficit hyperactivity disorder (ADHD) in children and adolescents between 6 and 17 years old.

The new device, called the Help System for Neuropsychiatric Evaluation based on Electroencephalogram (NEBA), uses electroencephalogram technology, a test that allows recording different kinds of electrical impulses emitted by neurons in the brain, the frequency with which impulses are emitted (number of times per second).

The new system will help confirm the diagnosis of ADHD, or differentiate it from other disorders with similar symptoms

It is a non-invasive test, which lasts between 15 and 20 minutes, and serves to calculate the relationship between two frequencies of brain waves, known as theta and beta waves, since it has been proven that the theta / beta ratio is higher in those children and adolescents who suffer from ADHD.

The 'NEBA System' will be part of a complete medical and psychological evaluation and, according to the results obtained in the tests that have been carried out to verify its effectiveness, it can help confirm the diagnosis of ADHD, and will also serve to support the indication of the medical specialist to perform additional tests that confirm the presence of the disorder, or establish a differential diagnosis with respect to other medical or behavioral problems that present symptoms similar to those of ADHD.

ADHD treatment device for children approved by FDA (November 2019).